Pregabalin Capsule
Product Images NDC 82804-247

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82804-247). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-247-90 (Image 01)

This is a description of a medication called Pregabalin 100mg in capsule form. The capsules are white to off-white in color and contain granular powder. Each capsule contains 100mg of pregabalin and is filled in hard gelatin capsules. It is recommended to dispense the accompanying Medication Guide to each patient. The medication is re-labeled by Proficient Rx LP and manufactured by MSN Laboratories Private Limited in India. The capsules are imprinted with "PGBN" on the body and "100" on the cap. The medication should be stored at 25°C and kept out of the reach of children.*

FDA Label Image

Equation (Pregabain Gault Equation)

This text provides a formula to calculate creatinine clearance (CLCr) based on age, weight, and serum creatinine levels, with an adjustment for female patients.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This is a chart showing the percentage of patients improved with different doses of Pregabalin and a placebo, based on the percentage improvement in pain from baseline. It indicates the effectiveness of Pregabalin at different dosages in managing pain compared to a placebo.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This data chart shows the percentage of patients who experienced improvement in pain after taking Pregabalin 100 mg three times a day compared to a placebo. The chart ranges from less than 10% to 100% improvement in pain from baseline, indicating the effectiveness of Pregabalin in managing pain.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This data table shows the percentage of patients who experienced improvement in pain from baseline when taking different doses of Pregabalin (300mg, 150mg, 75mg two times a day) compared to a placebo. The graph demonstrates a dose-dependent increase in improvement, with the highest dose of 300mg showing the most significant improvement. This information can be used to analyze the efficacy of Pregabalin in treating pain.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This text provides data on the percentage of patients improved based on different dosages of Pregabalin and a placebo. It also shows the percentage improvement in pain from baseline. The text suggests that a higher dose of Pregabalin may lead to greater improvements in patients.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This data provides information on the percent of patients improved with different dosages of Pregabalin and Placebo. It shows the percentage improvement in pain from baseline, ranging from greater than 10% to greater than 90%. The dosages of Pregabalin tested were 100 mg three times a day and 50 mg three times a day, along with a Placebo control group.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This text displays responder rates (%) for different doses and frequencies of a study drug compared to a placebo. The table shows the percentage of patients who responded to treatment in each group, with some comparisons being statistically significant. The study includes different dosages (50mg/day, 150 mg/day, 300 mg/day, 600 mg/day) administered either twice a day (BID) or three times a day (TID). The data suggests that higher dosages of the study drug may result in higher responder rates.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This text presents statistical data regarding different doses of a medication. The table displays p-values for various doses, highlighting significant values below a certain threshold. The doses are measured in milligrams per day, with the placebo labeled as a reference point. The results suggest a strong statistical significance for certain doses as indicated by the p-values, with a clear emphasis on the significance levels provided.*

FDA Label Image

Pregabalin-figure-08 (Pregabalin Figure 08)

This is a list of responder rates for different treatments in a study. The responder rates are presented as percentages, including 406%, 2.1%, 26%, and 93-103%. One of the treatments mentioned is "Placsbo" at doses of 25 mg/kg/day and 10 mg/kg/day.*

FDA Label Image

Pregabalin-figure-09 (Pregabalin Figure 09)

FDA Label Image

Fig-10 (Pregabalin Figure 10)

This text provides information on estimated subjects without LIR (likely inadequate response) at different percentage levels for Pregabalin and Placebo over a certain number of days. The data shows a comparison between Pregabalin and Placebo in terms of efficacy or response rates.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

This information provides the percentage of subjects who showed improvement from baseline to week 12 for the drug Pregabalin versus a placebo, as noted on the graph.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This text provides information on the percentage of subjects improved over time from baseline to Week 16 with the use of Pregabalin compared to Placebo. The data is presented in a tabular format with percentage ranges, indicating the improvement at different levels.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.